More than 50 volunteers, type 2 diabetics and healthy individuals, have participated to GlucoModicum clinical trials during May 2019 – July 2019. GlucoModicum in-house prototype was tested in the clinical trials. Clinical trials were successful.
Initial results of the clinical pilot indicate that GlucoModicum’s non-invasive technology may provide an optimal performance for type 2 diabetics to manage their health. At the moment there are no other non-invasive technologies in the market which can be used for this purpose.
